Keyphrases
India
84%
Tuberculosis
48%
Pune
39%
AIDS/HIV
35%
Antiretroviral Therapy
33%
Household Contacts
28%
People Living with HIV (PLHIV)
22%
Pregnant Women
22%
Confidence Interval
21%
Pulmonary Tuberculosis
20%
Tuberculosis Disease
19%
Isoniazid Preventive Therapy
18%
Multidrug-resistant Tuberculosis (MDR-TB)
16%
Tuberculosis Incidence
14%
TB Treatment
14%
HIV Patients
13%
Tuberculosis Treatment
13%
Tuberculosis Treatment Outcomes
12%
Active Tuberculosis
12%
Type 1 Diabetes Mellitus (T1DM)
11%
Tuberculosis Diagnosis
11%
Antiretroviral Therapy Initiation
11%
Tuberculin Skin Test
11%
CD4 Count
10%
Latent Tuberculosis Infection
10%
Rifapentine
9%
Tuberculosis Patients
9%
Risk Factors
9%
High Risk
9%
Advanced HIV Disease
9%
Tuberculosis Infection
8%
Efavirenz
8%
Interferon-gamma Release Assay
8%
Mycobacterium Tuberculosis (M. tb)
8%
Postpartum Women
7%
Nevirapine
7%
During Pregnancy
7%
Neonatal Intensive Care Unit
7%
High Burden
7%
Adjusted Odds Ratio
7%
HIV in Pregnancy
7%
Unfavorable Outcome
6%
Soluble CD14 (sCD14)
6%
Incidence Rate
6%
Interleukin-6
6%
Treatment Failure
6%
Pediatric Tuberculosis
6%
Inflammation
6%
High Prevalence
6%
Bloodstream Infection
6%
Medicine and Dentistry
Human Immunodeficiency Virus
82%
Disease
31%
Tuberculosis
28%
Antiretroviral Therapy
25%
Prophylaxis
25%
Household
22%
Isoniazid
18%
Infection
16%
Prevalence
14%
Mantoux Test
14%
Lung Tuberculosis
12%
Tuberculosis Treatment
12%
Multidrug Resistant Tuberculosis
11%
Latent Tuberculosis
10%
Human Immunodeficiency Virus Infection
9%
Pediatrics
9%
Arm
9%
Odds Ratio
8%
Diabetes Mellitus
8%
Interferon Gamma Release Assay
7%
Mycobacterium Tuberculosis
7%
Symptom
7%
COVID-19
7%
Rifampicin
7%
Neonatal Intensive Care Unit
7%
Nevirapine
6%
QuantiFERON
6%
Bloodstream Infection
6%
Health Care Provider
5%
Diabetes
5%
Cohort Analysis
5%
Drug Resistant Tuberculosis
5%
Drug Sensitivity
5%
Neonate
5%
Diagnosis
5%
Pharmacology, Toxicology and Pharmaceutical Science
HIV
100%
Isoniazid
37%
Disease
33%
Tuberculosis
26%
Pharmacokinetics
15%
Prevalence
14%
Tuberculin
14%
Rifampicin
14%
Infection
13%
Lung Tuberculosis
11%
Inflammation
10%
Biological Marker
10%
Multi-Drug-Resistant Tuberculosis
9%
Rifapentine
9%
Latent Tuberculosis
8%
Efavirenz
8%
Clinical Trial
8%
Diabetes Mellitus
8%
C Reactive Protein
7%
Human Immunodeficiency Virus Infection
7%
Nevirapine
7%
Symptom
6%
Vitamin D
6%
Gamma Interferon
6%
Drug Resistant Tuberculosis
6%
Recurrent Disease
5%
Anemia
5%
Disease Exacerbation
5%